| Indication | generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive |
| Drug | cemdisiran |
| Mechanism of Action | C5-directed siRNA |
| Company | Regeneron Pharmaceuticals, Inc. |
| Trial Phase | Phase 3 |
| Trial Acronym | NIMBLE |
| Category | Regulatory Milestone |
| Sub Category | Approval Granted |
| Therapeutic Area | Neuroscience |
| Approval Date | November 18, 2026 |
| Regulatory Body | U.S. Food and Drug Administration (FDA) |
| Dosing Frequency | Four times a year |
| Administration Route | Subcutaneous |
| Patient Subpopulation | Adults, anti-acetylcholine receptor (AChR) antibody-positive |
| Primary Endpoint | MG-ADL total score change from baseline to week 24 |
| Key Secondary Endpoint | QMG total score change from baseline to week 24 |
| Common Adverse Reactions | Injection site reactions, viral infections, urinary tract infections |
| Safety Information | Boxed Warning for serious meningococcal infections, Livsayis Risk Evaluation and Mitigation Strategy (REMS) |
| Regulatory Status EU | Under review, decision anticipated H2 2027 |
FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis
Regeneron Pharmaceuticals announced that the U.S. FDA has approved Livsayis (cemdisiran) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. Livsayis is the first and only approved siRNA therapy for gMG and the only FDA-approved gMG treatment administered subcutaneously four times a year. The approval is based on results from the Phase 3 NIMBLE trial, which demonstrated rapid, deep, and sustained disease control, maintained throughout three-month dosing intervals. Livsayis showed significant improvements in MG-ADL and QMG total scores compared to placebo at 24 weeks, with clinically meaningful benefits observed as early as two weeks.
- Livsayis demonstrated significant efficacy in the Phase 3 NIMBLE trial, showing a 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at 24 weeks, compared to a 2.2-point improvement with placebo (placebo-adjusted improvement of 2.3 points, p=0.0005). A greater proportion of Livsayis patients (76.6%) achieved at least a 3-point MG-ADL improvement versus placebo (44.1%, p<0.001).
- The drug also achieved a 4.2-point improvement in Quantitative Myasthenia Gravis (QMG) total score at 24 weeks, compared to a 1.5-point improvement with placebo (placebo-adjusted improvement of 2.8 points, p=0.0015). Clinically meaningful benefits in MG-ADL were observed as early as two weeks, deepening over time and demonstrating sustained disease control through 24 weeks without waning efficacy.
- Livsayis is a novel, complement component factor 5 (C5)-directed small interfering RNA (siRNA) therapeutic, functioning by reducing circulating C5 protein levels to limit terminal complement activation, a key driver of gMG. This mechanism makes it the first and only approved siRNA therapy for gMG and the only FDA-approved gMG treatment administered subcutaneously four times a year, significantly reducing treatment burden.
Addressing Unmet Needs in Generalized Myasthenia Gravis Treatment
Despite established therapies being effective in most patients with generalized myasthenia gravis, some patients do not respond or they experience intolerable adverse events, highlighting the need for better tolerated, targeted therapies for treatment-refractory disease. Long-term reliance on corticosteroids and conventional immunosuppressants carries substantial toxicity while still leaving a refractory subgroup with limited evidence-based options.
Treatment refractoriness persists in a meaningful subgroup: approximately 10-15% of patients with generalized AChR antibody-positive MG develop refractoriness to standard immunosuppressive therapies, with approximately 20% of patients with MG described as refractory to conventional immunosuppressive therapy.
Corticosteroid toxicity limits long-term use: long term steroid use carries substantial risks of severe adverse side effects, including weight gain of about 30 kg, steroid myopathy, cushingoid facies with bilateral exophthalmos, and increased annualized risk of new-onset diabetes (hazard ratios 1.32-1.76), infections (1.19-1.25), osteoporosis (1.33-1.69), cardiovascular disease (1.19-1.31), glaucoma (hazard ratio 1.81 at high dose) and depression, plus higher risk of major osteoporotic fracture with high dose glucocorticoid use (>7.5 mg/day).
Conventional immunosuppressants have delayed and difficult-to-prove benefit: non-steroidal immunosuppressive drugs have a delayed-onset effect and evidence of their efficacy appears to be difficult to obtain, compounded by a fluctuating disease course involving weakness that may be difficult to assess quantitively.
Acute rescue therapies fail in a proportion of crises: while plasma exchange (PLEX) and intravenous immunoglobulins (IVIG) are standard first-line therapies for myasthenic crisis, approximately 30% of patients may show suboptimal response.
Novel targeted agents bring monitoring and access constraints: these medications require vaccination and close monitoring for infections and hypersensitivity reactions, though challenges in cost and access remain, and patients with thymomatous MG exhibited a poorer response to efgartigimod and required two infusion cycles.
Unpacking Livsayis's C5-Directed siRNA Efficacy in gMG
The Phase 3 RAISE study (NCT04115293; N = 174) evaluated daily, self-administered, subcutaneous zilucoplan 0.3 mg/kg versus placebo for 12 weeks in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Zilucoplan is described as a macrocyclic peptide complement component 5 inhibitor. Mean (standard error) change from baseline to Week 12 in Myasthenia Gravis Activities of Daily Living score was -4.22 (0.71) with zilucoplan versus -2.61 (0.50) with placebo in the subgroup without prior immunoglobulin/PLEX, and -4.93 (0.54) versus -2.94 (0.50) in the subgroup with prior immunoglobulin/PLEX. Zilucoplan was well tolerated with a similar safety profile in both subgroups.
The Phase 3 ADAPT trial (NCT03669588) evaluated efgartigimod 10 mg/kg versus placebo administered as four once-weekly infusions per cycle for 26 weeks in acetylcholine receptor antibody-positive participants. In total, 129 AChR-Ab+ participants were included (efgartigimod, n = 65; placebo, n = 64). Across all subgroups, higher MG-ADL and QMG responder rates were observed in participants treated with efgartigimod versus placebo during cycles 1 and 2. Rates of treatment-emergent adverse events were similar between participants treated with efgartigimod and placebo, regardless of concomitant gMG treatment type.
In real-world settings, the ZILU25 multicenter observational study evaluated daily subcutaneous self-administered zilucoplan in AChR-positive generalized myasthenia gravis, with 54 patients (37 females, aged 57.3) receiving zilucoplan with a mean follow-up of 26.4 weeks. A clinical meaningful and significant reduction of MG-ADL, QMG, MGC and MG-QOL-15 scores from W4 to W12 and sustained at W24 was observed, with MG-ADL responder rate of 75.6 % at W12 and 82.9 % at W24, minimal symptoms expression in 55.6 % of patients at W48, and mean reduction of the daily prednisone dose of 8.3 mg at W24. Zilucoplan was well-tolerated. In an Italian multicenter retrospective study of ravulizumab, a monoclonal antibody targeting C5, in 24 anti-AChR positive generalized myasthenia gravis patients with median follow-up duration of 26 weeks (range 10-74, IQR 26-42), MG-ADL and QMG scores showed a significant decrease with respect to baseline (p < 0.001), minimal symptom expression was achieved by 37.5% patients at the last available follow-up, and tapering of prednisone daily dosage was possible in 76% of patients, while three patients discontinued treatment, one patient experienced a myasthenic exacerbation and needed rescue therapy, infectious adverse events were reported in 5/24 patients, and a Stevens-Johnson syndrome in one patient.
Understanding Livsayis's Safety Profile and REMS Program
Cemdisiran has been evaluated for safety and tolerability across IgA nephropathy, paroxysmal nocturnal hemoglobinuria (PNH), healthy subjects, and generalised myasthenia gravis. Across studies, cemdisiran was generally well tolerated with most adverse events mild or moderate and transient, and no new safety signals limiting further evaluation as monotherapy or in combination with C5 antibody therapy.
IgA nephropathy phase 2 trial: Over 36 weeks, most adverse events were mild or moderate and transient; the most common adverse event after cemdisiran treatment was injection-site reaction (41%). Treatment with cemdisiran 600 mg every 4 weeks was described as well tolerated.
Phase 1/2 study in healthy adults and PNH: Cemdisiran was generally well tolerated. Overall, 75%, 89%, and 100% of subjects in Parts A, B, and C, respectively, experienced ≥1 non-serious adverse event (AE). Most events were Grade 1 or 2 in severity and the most common AEs included nasopharyngitis and headache.
NIMBLE phase 3 trial in generalised myasthenia gravis: The proportion of participants with at least one adverse event during the 24-week double-blind treatment period was 54 (69%) of 78 in the cemdisiran group, 65 (81%) of 80 in the combination group, 40 (82%) of 49 in the pozelimab group, and 54 (77%) of 70 in the placebo group. The most common adverse event in the cemdisiran group was upper respiratory tract infection (nine [12%] of 78 patients), which occurred at a similar incidence in the placebo group (eight [11%] of 70). No serious or meningococcal infections occurred in the cemdisiran group. Adverse events leading to treatment discontinuation occurred in two participants (3%) in the placebo group and one participant (2%) in the pozelimab group. No deaths occurred during the double-blind treatment period. Two deaths occurred after the double-blind treatment period, one of which was assessed as treatment-related by the investigator but not treatment-related by the sponsor.
Phase 2 PNH combination trial of pozelimab and cemdisiran: While most patients (66.7%) experienced treatment-emergent adverse events, the majority of these events were mild to moderate in severity. No meningococcal infections, thrombotic events, or deaths were reported. Combination treatment was described as generally well tolerated.
Pharmacokinetic and pharmacodynamic study in healthy subjects and PNH: One of 48 subjects tested transiently positive for antidrug antibody with low titer, with no impact on PK or PD. Cemdisiran was reported to have low immunogenicity and acceptable safety profiles enabling low, infrequent SC dosing.
Frequently Asked Questions
References
- [1] Akhtar M, Akhtar M et al.. Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis. Clinical neurology and neurosurgery. 2025 Jul. 40288289
- [2] Habib AA, Drużdż A et al.. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. Journal of neuromuscular diseases. 2025 Mar. 40034001
- [3] Siddiqi ZA, Qi CZ et al.. Cost-Effectiveness Analysis of Efgartigimod vs Chronic Immunoglobulin for the Treatment of Myasthenia Gravis in Canada. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2025 Oct 27. 41139802
- [4] Filippakopoulou E, Gavriilaki M et al.. Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis. Journal of neurology. 2026 Apr 2. 41925914
- [5] Devalaraja-Narashimha K, Huang C et al.. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PloS one. 2022. 35709087
- [6] Parisi M, Molitierno N et al.. FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report. Frontiers in immunology. 2026. 42404894
- [7] Versino F, Fattizzo B. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. International journal of laboratory hematology. 2024 May. 38622956
- [8] Jiang L, Wei J et al.. Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives. Frontiers in neurology. 2026. 42358938
- [9] Jang JH, Wong RSM et al.. Safety, Efficacy, and Patient-Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria. EJHaem. 2025 Aug. 40708708
- [10] Grimm SL, Fierz FC et al.. The Spurious Palsy-Fluctuation of Ocular Myasthenia Gravis Symptoms Characterized by Orthoptics. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2025 Dec 1. 40198267
- [11] Xu XQ. [Clinical efficacy of Yiqi Qushi Recipe in treating myasthenia gravis and observation of its immunomodulatory effects]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2013 Feb. 23646470
- [12] Park HS, Kim K et al.. Risk of fracture in patients with myasthenia gravis: a nationwide cohort study in Korea. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2024 Jul 23. 38477782
- [13] Qi CZ, Lin Y et al.. Impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network. Journal of the neurological sciences. 2026 Feb 15. 41534441
- [14] Rossini E, Di Stefano V et al.. Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience. Journal of neurology. 2025 May 14. 40366475
- [15] Filippone EJ, Gulati R et al.. The road ahead: emerging therapies for primary IgA nephropathy. Frontiers in nephrology. 2025. 39968279
- [16] Yang Q, Yu S et al.. Perioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series. Journal of neuroimmunology. 2026 Nov. 42462363
- [17] Ji Y, Zhou S et al.. Clinical heterogeneity, treatment patterns, and outcomes of advanced-age-onset myasthenia gravis in China: a retrospective cohort study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2025 Nov. 40865296
- [18] Silvestri NJ. Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center. Muscle & nerve. 2025 Mar. 39744896
- [19] Sharma I, Panta R. Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine. Cureus. 2025 Dec. 41573494
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com














